



Karolinska
Institutet

Utilisation of Healthcare in Children Born to Lymphoma Survivors

Presentation at the 11th NordicEpi conference in Copenhagen

Joshua P. Entrop, Viktor Wintzell, Caroline E. Dietrich, Anna Marklund, Ingrid Glimelius, Tarec C. El-Galaly, Karin E. Smedby, and Sandra Eloranta

Background

- Advances in lymphoma treatments lead to a rising population of young adult lymphoma survivors.
- Previous studies found an increased risk of non-severe birth complications in children born to lymphoma survivors.
- No studies investigated impacts of lymphoma and its treatments on paediatric outcomes in children born to lymphoma survivors.





Figure 1 Average annual number of newly diagnosed lymphoma patients in Sweden between 2012 and 2021. Source: NORDCAN



Methods

- Estimated rates of in-/outpatient visits, and drug dispensations
- Explored patterns of healthcare utilisation using tree based scan statistics
 - Method for comparing observed and expected proportion of exposed individuals in each drug class.




Figure 3 Visualisation of the cuts on the ICD-10 tree. Ch: ICD Chapter

$$\text{LLR}(j) = \ln \left[\frac{\overbrace{(q_{1j})^{n_{1j}} (q_{0j})^{n_{0j}}}^{\text{Observed no. of exposed and unexposed in cut } j}}{\underbrace{(p)^{n_{1j}} (1-p)^{n_{0j}}}_{\text{Expected no. of exposed and unexposed in cut } j}} \right] \times \mathbb{I}(q_{1j} > p)$$

Results

	Children born to lymphoma survivors		Children born to comparators	
	No.	(%)	No.	(%)
Total	1040	(16.67)	5200	(83.33)
Females	496	(47.70)	2560	(49.20)
Mother's age at birth				
18-30	417	(42.20)	2128	(43.10)
30-40	570	(57.80)	2809	(56.90)
Parent with lymphoma				
Mother	491	(47.10)	-	-
Father	549	(52.70)	-	-

Table 1 Baseline characteristics of the study population

Results cont'd

	No. visits	Inc. rate (95%)	Rate ratio (95%)
Children born to lymphoma survivors	788	0.42 (0.39-0.44)	1.13 (1.04-1.22)
Children born to lymphoma-free parents	3842	0.37 (0.36-0.38)	Ref.

Table 2 Rates of in-and outpatient visits in children born to lymphoma survivors and children born to lymphoma-free parents.




Figure 4 No. of in-/outpatient visits and drug dispensations per child in children born to lymphoma survivors and children born to lymphoma-free parents.

Results cont'd

	Children born to lymphoma survivors		Children born to comparators		Risk Ratio	Risk Difference	P-value ^a
	Events	5-year risk	Events	5-year risk			
Cuts (ICD-10 codes)							
D37-D48 - Neoplasms of uncertain or unknown behavior	7	0.67%	7	0.13%	5.00	0.54	0.571
P701 - Syndrome of infant of a diabetic mother	8	0.77%	11	0.21%	3.64	0.56	0.849
B25 - Cytomegaloviral disease	3	0.29%	1	0.02%	15.00	0.27	0.861
D569 - Thalassaemia, unspecified	3	0.29%	1	0.02%	15.00	0.27	0.861
Ch. VIII - Diseases of the ear and mastoid process	212	20.38%	870	16.73%	1.22	3.65	0.957
R70-R79 - Abnormal findings on examination of blood, without diagnosis	6	0.58%	7	0.13%	4.29	0.44	0.965
G00-G09 - Inflammatory diseases of the central nervous system	6	0.58%	7	0.13%	4.29	0.44	0.965
P211 - Mild and moderate birth asphyxia	13	1.25%	27	0.52%	2.41	0.73	0.968
G50-G59 - Nerve, nerve root and plexus disorders	5	0.48%	5	0.10%	5.00	0.38	0.974
P13 - Birth injury to skeleton	4	0.38%	3	0.06%	6.67	0.33	0.979

Table 3 Table 1 The 10 most likely clusters of excess health-care utilisation on the ICD-10 tree obtained from the tree-based scan statistic ranked by their log-likelihood ratio. ^aP-values are obtained from Monte-Carlo simulations and are adjusted for multiple-testing. Abbreviations: Ch, ICD-10 chapter.

Discussion

Strength

- Explorative approach
- Direct adjustment for multiple-testing

Limitations

- Statistical power




Figure 5 A) LLR test distribution of the maximum LLRs in each Monte-Carlo Simulation highlighting the $P < 0.05$ cut of at 6.58 (dashed line). B) LLRs across different scenarios assuming a study population of 1 020 exposed and 5 100 unexposed individuals.

Conclusion

Children born to lymphoma survivors have an overall increased health care utilisation which is distributed across a panorama of different diseases.

Contact Information



joshua.entrop@ki.se



joshua-entrop.com

Funders



CANCERFONDEN



ÅKE WIBERGS STIFTELSE



**Karolinska
Institutet**